{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:57:28Z","timestamp":1782435448010,"version":"3.54.5"},"reference-count":39,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Introduction: Cannabis is listed as a Schedule I substance under the Controlled Substances Act of 1970, meaning the US federal government defines it as an illegal drug that has high potential for abuse and no established medical use; however, half of the states in the nation have enacted \u201cmedical marijuana\u201d (MM) laws. Clinicians must be aware of the evidence for and against the use of MM in their patients who may consider using this substance.<\/jats:p>\n               <jats:p>Methods: A PubMed database search was performed using the text string: \u201cCannabis\u201d[Mesh] OR \u201cMarijuana Abuse\u201d[Mesh] OR \u201cMedical Marijuana\u201d[Mesh] OR \u201cMarijuana Smoking\u201d[Mesh] OR \u201ccannabi*\u201d OR \u201ctetrahydrocannabinol.\u201d The search was further limited to randomized clinical trial publications in English on human subjects to identify articles regarding the therapeutic use of phytocannabinoids for psychiatric and neurologic disorders. Commercially available products (ie, dronabinol, nabilone, nabiximols) and synthetic cannabinoids were excluded from the review.<\/jats:p>\n               <jats:p>Results: Publications were identified that included patients with dementia, multiple sclerosis, Parkinson disease, Huntington disease, schizophrenia, social anxiety disorder, depression, tobacco use disorder, and neuropathic pain.<\/jats:p>\n               <jats:p>Discussion: There is great variety concerning which medical conditions are approved for treatment with MM for either palliative or therapeutic benefit, depending on the state law. It is important to keep an evidence-based approach in mind, even with substances considered to be illegal under US federal law. Clinicians must weigh risks and benefits of the use of MM in their patients and should ensure that patients have tried other treatment modalities with higher levels of evidence for use when available and appropriate.<\/jats:p>","DOI":"10.9740\/mhc.2017.01.029","type":"journal-article","created":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T19:05:44Z","timestamp":1483470344000},"page":"29-38","source":"Crossref","is-referenced-by-count":23,"title":["Evidence for the use of \u201cmedical marijuana\u201d in psychiatric and neurologic disorders"],"prefix":"10.9740","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8882-1094","authenticated-orcid":false,"given":"Christopher","family":"Noel","sequence":"first","affiliation":[{"name":"(Corresponding author) Assistant Professor of Pharmacy Practice, St John Fisher College Wegman's School of Pharmacy, Rochester, New York; Clinical Pharmacist, University of Rochester Medical Center, Rochester, New York, cnoel@sjfc.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"24","key":"2020060307304900900_i2168-9709-7-1-29-b01","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1001\/jama.2015.6199","article-title":"Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review","volume":"313","author":"Hill","year":"2015","journal-title":"JAMA"},{"key":"2020060307304900900_i2168-9709-7-1-29-b02","article-title":"New York State Medical Marijuana Program","year":"2016","journal-title":"About the medical marijuana program [Internet]"},{"issue":"8","key":"2020060307304900900_i2168-9709-7-1-29-b03","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem Biodivers"},{"issue":"24","key":"2020060307304900900_i2168-9709-7-1-29-b04","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"issue":"8-9 Suppl","key":"2020060307304900900_i2168-9709-7-1-29-b05","doi-asserted-by":"crossref","first-page":"413S","DOI":"10.1002\/j.1552-4604.1981.tb02621.x","article-title":"Treatment of human spasticity with delta 9-tetrahydrocannabinol","volume":"21","author":"Petro","year":"1981","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2020060307304900900_i2168-9709-7-1-29-b06","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1300\/J251v07n01_04","article-title":"Delta-9-THC in the treatment of spasticity associated with multiple sclerosis","volume":"7","author":"Ungerleider","year":"1988","journal-title":"Adv Alcohol Subst Abus"},{"issue":"3","key":"2020060307304900900_i2168-9709-7-1-29-b07","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/clpt.1994.33","article-title":"Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers","volume":"55","author":"Greenberg","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2020060307304900900_i2168-9709-7-1-29-b08","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1212\/WNL.58.9.1404","article-title":"Safety, tolerability, and efficacy of orally administered cannabinoids in MS","volume":"58","author":"Killestein","year":"2002","journal-title":"Neurology"},{"issue":"9395","key":"2020060307304900900_i2168-9709-7-1-29-b09","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"2020060307304900900_i2168-9709-7-1-29-b10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","article-title":"Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study","volume":"10","author":"Vaney","year":"2004","journal-title":"Mult Scler"},{"issue":"12","key":"2020060307304900900_i2168-9709-7-1-29-b11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","article-title":"Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up","volume":"76","author":"Zajicek","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2020060307304900900_i2168-9709-7-1-29-b12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","article-title":"The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)","volume":"17","author":"Freeman","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"11","key":"2020060307304900900_i2168-9709-7-1-29-b13","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/jnnp-2012-302468","article-title":"Multiple sclerosis and extract of cannabis: results of the MUSEC trial","volume":"83","author":"Zajicek","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2020060307304900900_i2168-9709-7-1-29-b14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"issue":"11","key":"2020060307304900900_i2168-9709-7-1-29-b15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2020060307304900900_i2168-9709-7-1-29-b16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J Psychopharmacol"},{"issue":"6","key":"2020060307304900900_i2168-9709-7-1-29-b17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"2020060307304900900_i2168-9709-7-1-29-b18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res"},{"issue":"6","key":"2020060307304900900_i2168-9709-7-1-29-b19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction","volume":"57","author":"D'Souza","year":"2005","journal-title":"Biol Psychiatry"},{"key":"2020060307304900900_i2168-9709-7-1-29-b20","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"issue":"9","key":"2020060307304900900_i2168-9709-7-1-29-b21","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict Behav"},{"issue":"6","key":"2020060307304900900_i2168-9709-7-1-29-b22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jpain.2007.12.010","article-title":"A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain","volume":"9","author":"Wilsey","year":"2008","journal-title":"J Pain"},{"issue":"14","key":"2020060307304900900_i2168-9709-7-1-29-b23","doi-asserted-by":"publisher","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ"},{"issue":"2","key":"2020060307304900900_i2168-9709-7-1-29-b24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","article-title":"Low-dose vaporized cannabis significantly improves neuropathic pain","volume":"14","author":"Wilsey","year":"2013","journal-title":"J Pain"},{"issue":"2","key":"2020060307304900900_i2168-9709-7-1-29-b25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"issue":"17","key":"2020060307304900900_i2168-9709-7-1-29-b26","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","article-title":"Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Koppel","year":"2014","journal-title":"Neurology"},{"key":"2020060307304900900_i2168-9709-7-1-29-b27","unstructured":"Patel \n              A, \n            \n            \n              Fee \n              D, \n            \n            \n              Brust \n              JCM, \n            \n            \n              Song \n              S, \n            \n            \n              Miller \n              TR, \n            \n            \n               Narayanaswami \n              P\n            . \n          American Academy of Neurology Position Statement: use of medical marijuana for neurologic disorders [Internet]. Minneapolis (MN): American Academy of Neurology [cited2016Sept 25]. Available from: https:\/\/www.aan.com\/uploadedFiles\/Website_Library_Assets\/Documents\/6.Public_Policy\/1.Stay_Informed\/2.Position_Statements\/3.PDFs_of_all_Position_Statements\/Final%20Medical%20Marijuana%20Position%20Statement.pdf"},{"key":"2020060307304900900_i2168-9709-7-1-29-b28","unstructured":"Zaman \n              T, \n            \n            \n              Rosenthal \n              RN, \n            \n            \n              Renner \n              JA Jr, \n            \n            \n              Kleber \n              HD, \n            \n            \n              Milin \n              R. \n            \n          \n          Resource document on marijuana as medicine, 2013 [Internet]. Washington: American Psychiatric Association [cited2016Sept 25]. Available at: https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Directories\/Library-and-Archive\/resource_documents\/rd2013_MarijuanaMedicine.pdf"},{"issue":"2","key":"2020060307304900900_i2168-9709-7-1-29-b29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/0269881105049040","article-title":"Cannabis as a risk factor for psychosis: systematic review","volume":"19","author":"Semple","year":"2005","journal-title":"J Psychopharmacol"},{"issue":"9584","key":"2020060307304900900_i2168-9709-7-1-29-b30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","article-title":"Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review","volume":"370","author":"Moore","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"2020060307304900900_i2168-9709-7-1-29-b31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/archgenpsychiatry.2011.5","article-title":"Cannabis use and earlier onset of psychosis: a systematic meta-analysis","volume":"68","author":"Large","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"2020060307304900900_i2168-9709-7-1-29-b32","unstructured":"Cannabis [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration [revised2015Oct; cited 2016 May 16].Available from: http:\/\/www.samhsa.gov\/atod\/cannabis"},{"issue":"1","key":"2020060307304900900_i2168-9709-7-1-29-b33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1055-9965.EPI-14-1026","article-title":"An epidemiologic review of marijuana and cancer: an update","volume":"24","author":"Huang","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"2020060307304900900_i2168-9709-7-1-29-b34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2146\/ajhp060471","article-title":"Medical marijuana and the developing role of the pharmacist","volume":"64","author":"Seamon","year":"2007","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"2020060307304900900_i2168-9709-7-1-29-b35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system?: a systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"23","key":"2020060307304900900_i2168-9709-7-1-29-b36","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial","volume":"84","author":"van den Elsen","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"2020060307304900900_i2168-9709-7-1-29-b37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington's disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"2020060307304900900_i2168-9709-7-1-29-b38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archpsyc.1973.01750330041007","article-title":"9 -Tetrahydrocannabinol in depressed patients","volume":"28","author":"Kotin","year":"1973","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"2020060307304900900_i2168-9709-7-1-29-b39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00004714-198306000-00004","article-title":"A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa","volume":"3","author":"Gross","year":"1983","journal-title":"J Clin Psychopharmacol"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/1\/29\/2095755\/mhc_2017_01_029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/1\/29\/2095755\/mhc_2017_01_029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:20:17Z","timestamp":1731687617000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/7\/1\/article-p29.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2017.01.029","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,1]]}}}